Swiss study tests cutting back on acid reflux meds
NCT ID NCT06129474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a program to help doctors and patients safely reduce or stop taking acid-reducing pills (proton pump inhibitors) when they are no longer needed. About 400 adults in Swiss primary care who take these pills daily will be enrolled. The goal is to see if the program can lower pill use without causing worse heartburn or indigestion.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient of a participating GP. 2. Age: minimum 18 years old. 3. Daily PPI intake for minimum 8 weeks. 4. PPI in one of the following doses: * minimum 40mg/day pantoprazole; * minimum 40mg/day omeprazole; * more than 30mg/day lansoprazole; * more than 30mg/day dexlansoprazole; * more than 20mg/day esomeprazole; * more than 20mg/day rabeprazole. 5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment. Exclusion Criteria: 1. Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months. 2. Unable to provide informed consent. 3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as: * History of bleeding ulcer. * Peptic ulcer due to cause other than NSAID or H. Pylori. * Barrett's oesophagus. * Severe erosive reflux disease (Los Angeles grade C/D). * GERD with symptoms or complications (oesophageal ulcer, peptic stricture). * Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.) 4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below. Medications (any dose): * Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days. * Antiplatelet therapy. * Additional antiplatelet therapy (e.g., ticagrelor or similar). * Anticoagulant(s). * Systemic steroid(s) for more than 1 month. Risk factors: * History of gastrointestinal ulcer. * Age of 75 years and older. * Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use. * Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inappropriate prescribing are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Prof. Dr. med. Dr. phil. Sven Streit
NOT_YET_RECRUITINGBern, 3012, Switzerland
-
University of Bern
RECRUITINGBern, 3012, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could probiotics soothe reflux? new study begins
- EHR nudges aim to curb sleep pill overuse in primary care
- New program aims to cut dangerous drug combinations in seniors
- Could a simple pill replace IV drips for bleeding ulcers?
- Nursing home drug safety study aims to cut risky prescribing
- New study aims to cut risky meds for seniors with pharmacist feedback